Crispr Therapeutics ((CRSP)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled ‘A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease’ aims to assess the safety and initial effectiveness of CTX112. This study is significant as it targets challenging autoimmune diseases like systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy, offering hope for patients with limited treatment options.
Intervention/Treatment: The intervention being tested is CTX112, a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy. These are allogeneic T cells genetically modified using CRISPR-Cas9 technology, intended to treat refractory autoimmune diseases.
Study Design: This is a Phase 1, single-arm, open-label, multicenter study. Participants receive CTX112 through IV infusion after lymphodepleting chemotherapy. The study uses a sequential intervention model with no masking, focusing on treatment as its primary purpose.
Study Timeline: The study began on March 10, 2025, with the latest update on August 5, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
Market Implications: This study update could positively influence Crispr Therapeutics’ stock performance, as successful outcomes may bolster investor confidence. The competitive landscape in gene editing and immunotherapy is intense, and advancements in CTX112 could position the company favorably against its peers.
The study is currently recruiting, with further details available on the ClinicalTrials portal.